Form 4: Unity Biotechnology Director Acquires Stock Options

Paul L. Berns, a director at Unity Biotechnology, acquired stock options for 10,000 shares on June 21, 2024.

Summary

• Paul L. Berns, a director of Unity Biotechnology, Inc. (UBX), filed a Form 4 with the SEC.
• The form reports a transaction that occurred on June 21, 2024.
• Berns acquired stock options for 10,000 shares of Unity Biotechnology common stock at an exercise price of $1.38.
• The options vest 100% on the earlier of June 21, 2025, or the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.
• Following the transaction, Berns beneficially owns 10,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, and the transaction itself doesn't inherently indicate positive or negative sentiment. It's a neutral event.

Positives

• A director increasing their stake in the company can be seen as a positive signal.

Industry Context

Form 4 filings are routine disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates